文献速递贫血与红细胞疾病

静脉铁剂与口服铁剂一线治疗月经过多相关缺铁性贫血的成本效果

Cost-effectiveness of first-line IV vs oral iron for iron-deficiency anemia in women with heavy menstrual bleeding.
PubMed 文献 · Blood Adv · 2026-01-01

该研究用Markov模型模拟18至51岁月经过多合并缺铁性贫血女性,比较静脉铁右旋糖酐、静脉 ferumoxytol、静脉蔗糖铁与口服硫酸亚铁一线治疗的全生育期成本效果。静脉铁右旋糖酐最具成本效果,ICER为每QALY 28 600美元,在常用支付意愿阈值下支持将静脉铁作为一线选择。

要点

  • 静脉 ferumoxytol 和蔗糖铁成本更高且未较铁右旋糖酐额外增加QALY。
  • 结果支持扩大静脉铁可及性并减少治疗延迟和保险相关障碍。

核心结论

  • 静脉铁右旋糖酐一线治疗月经过多相关缺铁性贫血在常用支付意愿阈值下具有成本效果。

研究设计与样本

  • 研究采用Markov模型模拟18至51岁月经过多合并缺铁性贫血女性队列。
  • 比较一线静脉铁右旋糖酐、静脉 ferumoxytol、静脉蔗糖铁与口服硫酸亚铁治疗。
  • 成本和QALY从社会视角估算。

主要发现

  • 静脉铁右旋糖酐获得19.26 QALY、成本157 500美元;口服硫酸亚铁获得19.10 QALY、成本152 900美元。
  • 静脉铁右旋糖酐的增量成本效果比为每QALY 28 600美元。
  • 静脉 ferumoxytol 和蔗糖铁成本分别为158 300美元和163 500美元,且未较铁右旋糖酐额外增加QALY。
  • 静脉铁右旋糖酐在多种情景和敏感性分析中均保持成本效果。

临床怎么用

  • 可考虑将静脉铁右旋糖酐作为月经过多相关缺铁性贫血女性的一线治疗选项。
  • 需减少治疗延迟并降低保险相关障碍以扩大静脉铁可及性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Iron-deficiency anemia (IDA) affects nearly one-third of women globally, with heavy menstrual bleeding (HMB) being a significant risk factor among those of reproductive age. Despite the substantial burden of HMB-related IDA, patients often face delays in receiving effective treatment. Oral iron is typically used as first-line therapy, despite frequent gastrointestinal side effects and challenges in treatment adherence. This study evaluated the reproductive life span cost-effectiveness of first-line intravenous (IV) vs oral iron therapy for women with HMB and IDA. We developed a Markov model simulating a cohort of women aged 18 to 51 years, comparing first-line treatment with IV iron dextran, IV ferumoxytol, IV iron sucrose, or oral ferrous sulfate. Costs and quality-adjusted life years (QALYs) were estimated from the societal perspective. IV iron dextran was the cost-effective treatment, yielding 19.26 QALYs at a cost of $157 500, compared with 19.10 QALYs at $152 900 for oral ferrous sulfate. The incremental cost-effectiveness ratio for IV iron dextran was $28 600 per QALY. Treatment with IV ferumoxytol and iron sucrose cost $158 300 and $163 500, respectively, and did not provide additional QALY benefit compared with IV iron dextran, which remained the cost-effective treatment across a range of scenarios and sensitivity analyses. Our findings indicate that first-line treatment with IV iron dextran is the cost-effective strategy for managing IDA in women with HMB at commonly accepted willingness-to-pay thresholds. These results support expanding access to IV iron as a first-line option, and highlight the need to reduce treatment delays and insurance-related barriers.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wang D, Sra M, Ito S, et al. Cost-effectiveness of first-line IV vs oral iron for iron-deficiency anemia in women with heavy menstrual bleeding. Blood Adv. 2026. PMID: 41504430. doi:10.1182/bloodadvances.2025018315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。